secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001628280-24-044541
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M
------------------------------------------------------------------------

- Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
- Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.
- Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.
- Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).
- Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/0001628280-24-044541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/cdxc-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-044541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer